看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。4 T6 z; Q- |9 l3 }) @# q+ l4 r
) b+ `; Z& C9 U8 N9 n/ X7 {5 C
" Z9 K% Y, P# w7 F' e0 F. o& y+ HCurrently available feasibility data for possible combination strategies. 3 u H' |, \% p/ j, k& @& T* P" N3 `' N
————————————————————————————————; ^; S$ f, B+ d/ A* `
Combination Feasibility according to preliminary data
2 A3 Q& h$ W; C& B8 S——————————————————————————————————
: J+ P" {& b+ X m5 q2 XBevacizumab + sorafenib Yes, reduced dose
! z( s9 r( H0 e2 `, }" l- MBevacizumab + sunitinib† No 2 h8 E. n9 p5 T- N
Bevacizumab + temsirolimus Yes ; w3 W0 d D( ?$ Z* i
Bevacizumab + everolimus Yes 9 Y: ?9 g+ P7 p& r! a$ Q
Sorafenib + sunitinib ? / T, v: M8 `. X+ M: F
Sorafenib + temsirolimus Yes, reduced dose 1 X/ \1 B5 f! M( u; a! s5 u, F
Sorafenib + everolimus Yes, reduced dose ) K1 ~2 a* y( X+ n; l5 [
Sunitinib + temsirolimus† No " n m6 d$ h1 d0 F; {- @
Sunitinib + everolimus ? U e7 \+ c9 E% b1 H# w+ G
Temsirolimus + everolimus ? 0 X# y. ^( H; y" y
————————————————————& s# X' H- P' n& n" E* {8 A" [6 B/ _
†Led to US FDA warning.& d$ l1 F. t6 L Z$ T+ w
?: As yet unattempted combination.4 b$ @8 M( T8 x
|